Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 20, 2016 (10 years ago)

Propofol1% 10mg/mL injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Propofol1% 10mg/mL injection, 20 mL BD syringe, Rx Only, Compounded by PHARMAKON Pharmaceuticals, Noblesville, IN 46060, NDC 45183-0119-73

Affected NDC 45183-0119-73

Compare with the code on your package — it is the most precise check available.

Drug: Propofol

Recalling firm
Pharmakon Pharmaceuticals, Inc.
NDC code
45183-0119-73
Origin
IN, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1264-2016 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Propofol recalls

See all
Class II · Moderate risk

Diprivan (Propofol)

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-29 D-1116-2022
Class II · Moderate risk

Diprivan (Propofol)

cGMP deviations: Temperature abuse

Terminated Temperature excursion Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-10 D-1115-2022

Other recalls by Pharmakon Pharmaceuticals, Inc.

All 2016 recalls